Krka d. d (KRKG) Stock Overview
A generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for KRKG from our risk checks.
KRKG Community Fair Values
Create NarrativeSee what 41 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Krka, d. d. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €232.00 |
| 52 Week High | €251.00 |
| 52 Week Low | €150.50 |
| Beta | 0.48 |
| 1 Month Change | 0.87% |
| 3 Month Change | 14.85% |
| 1 Year Change | 38.51% |
| 3 Year Change | 123.08% |
| 5 Year Change | 142.17% |
| Change since IPO | 2,825.05% |
Recent News & Updates
Some Confidence Is Lacking In Krka, d. d.'s (LJSE:KRKG) P/E
Jan 11
Do Krka d. d's (LJSE:KRKG) Earnings Warrant Your Attention?
Dec 06Recent updates
Some Confidence Is Lacking In Krka, d. d.'s (LJSE:KRKG) P/E
Jan 11Do Krka d. d's (LJSE:KRKG) Earnings Warrant Your Attention?
Dec 06Is Krka, d. d. (LJSE:KRKG) Trading At A 21% Discount?
Nov 17Here's Why We Think Krka d. d (LJSE:KRKG) Is Well Worth Watching
Sep 01Krka, d. d.'s (LJSE:KRKG) Intrinsic Value Is Potentially 33% Above Its Share Price
Aug 14We Think Krka, d. d.'s (LJSE:KRKG) CEO Compensation Looks Fair
Jul 03Getting In Cheap On Krka, d. d. (LJSE:KRKG) Is Unlikely
Jun 23Krka d. d's (LJSE:KRKG) Upcoming Dividend Will Be Larger Than Last Year's
May 18Is There An Opportunity With Krka, d. d.'s (LJSE:KRKG) 28% Undervaluation?
May 08Should You Be Adding Krka d. d (LJSE:KRKG) To Your Watchlist Today?
Apr 01Shareholder Returns
| KRKG | SI Pharmaceuticals | SI Market | |
|---|---|---|---|
| 7D | -3.3% | -2.3% | -3.3% |
| 1Y | 38.5% | -1.9% | 43.4% |
Return vs Industry: KRKG exceeded the SI Pharmaceuticals industry which returned -1.3% over the past year.
Return vs Market: KRKG underperformed the SI Market which returned 42.4% over the past year.
Price Volatility
| KRKG volatility | |
|---|---|
| KRKG Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in SI Market | 6.9% |
| 10% least volatile stocks in SI Market | 3.1% |
Stable Share Price: KRKG has not had significant price volatility in the past 3 months compared to the SI market.
Volatility Over Time: KRKG's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 13,107 | Jože Colaric | www.krka.biz |
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company’s prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolism, central nervous system, oncology, pain relief, antiinfectives for systemic use, antidiabetics, and other products. It provides non-prescription products for oral cavity and pharynx; cough and cold; analgesics; nasal products; vitamin and mineral products; cerebral and peripheral circulation; vasoprotectives; health care products; and others.
Krka, d. d. Fundamentals Summary
| KRKG fundamental statistics | |
|---|---|
| Market cap | €7.07b |
| Earnings (TTM) | €398.80m |
| Revenue (TTM) | €2.01b |
Is KRKG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRKG income statement (TTM) | |
|---|---|
| Revenue | €2.01b |
| Cost of Revenue | €849.50m |
| Gross Profit | €1.16b |
| Other Expenses | €760.62m |
| Earnings | €398.80m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 12, 2026
| Earnings per share (EPS) | 13.09 |
| Gross Margin | 57.71% |
| Net Profit Margin | 19.85% |
| Debt/Equity Ratio | 0% |
How did KRKG perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/05 11:36 |
| End of Day Share Price | 2026/03/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Krka, d. d. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Simon Mather | Barclays |
| Stephane Sumar | BNP Paribas |
| Jamie Clark | BofA Global Research |